O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 8.5 GBX Market Closed
Market Cap: 34.3m GBX
Have any thoughts about
Ondine Biomedical Inc?
Write Note

Ondine Biomedical Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Net Change in Cash
-CA$10.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Net Change in Cash
-$6.7m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Net Change in Cash
-$6.5m
CAGR 3-Years
15%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Net Change in Cash
-CA$5.7m
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Net Change in Cash
CA$21.1k
CAGR 3-Years
N/A
CAGR 5-Years
-54%
CAGR 10-Years
-39%
MedMira Inc
XTSX:MIR
Net Change in Cash
CA$2.1m
CAGR 3-Years
N/A
CAGR 5-Years
88%
CAGR 10-Years
32%
No Stocks Found

Ondine Biomedical Inc
Glance View

Market Cap
34.3m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.22 GBX
Overvaluation 50%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Net Change in Cash?
Net Change in Cash
-10.1m CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Net Change in Cash amounts to -10.1m CAD.

What is Ondine Biomedical Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
39%

Over the last year, the Net Change in Cash growth was 39%.

Back to Top